Sab Biotherapeutics Stock Last Dividend Paid

SABSW Stock

USD 0.05 0.03 35.15%

SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SAB Biotherapeutics Company Last Dividend Paid Analysis

SAB Biotherapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

SAB Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue
Total Assets		0.98	-0.87	-0.56	0.26	0.92	0.26	0.69	0.98	-0.86	0.99	-0.65	0.86	0.07	-0.38	0.64
Total Stockholder Equity	0.98		-0.85	-0.57	0.3	0.9	0.32	0.54	1.0	-0.81	0.96	-0.64	0.86	0.17	-0.4	0.65
Net Debt	-0.87	-0.85		0.86	0.2	-0.91	0.16	-0.64	-0.85	0.61	-0.89	0.94	-0.96	-0.39	0.72	-0.91
Retained Earnings	-0.56	-0.57	0.86		0.59	-0.74	0.54	-0.31	-0.58	0.18	-0.59	0.95	-0.78	-0.75	0.79	-0.94
Accounts Payable	0.26	0.3	0.2	0.59		0.0	0.98	0.01	0.3	-0.56	0.2	0.49	-0.06	-0.66	0.5	-0.43
Long Term Debt	0.92	0.9	-0.91	-0.74	0.0		-0.02	0.65	0.9	-0.76	0.87	-0.75	0.83	0.22	-0.4	0.72
Net Receivables	0.26	0.32	0.16	0.54	0.98	-0.02		-0.06	0.32	-0.51	0.22	0.42	0.01	-0.58	0.37	-0.34
Total Liab	0.69	0.54	-0.64	-0.31	0.01	0.65	-0.06		0.53	-0.72	0.69	-0.46	0.53	-0.29	-0.16	0.34
Net Invested Capital	0.98	1.0	-0.85	-0.58	0.3	0.9	0.32	0.53		-0.8	0.96	-0.64	0.86	0.18	-0.4	0.66
Short Long Term Debt	-0.86	-0.81	0.61	0.18	-0.56	-0.76	-0.51	-0.72	-0.8		-0.79	0.31	-0.62	0.42	0.02	-0.28
Total Current Assets	0.99	0.96	-0.89	-0.59	0.2	0.87	0.22	0.69	0.96	-0.79		-0.7	0.89	0.14	-0.48	0.69
Capital Stock	-0.65	-0.64	0.94	0.95	0.49	-0.75	0.42	-0.46	-0.64	0.31	-0.7		-0.9	-0.61	0.89	-0.99
Net Working Capital	0.86	0.86	-0.96	-0.78	-0.06	0.83	0.01	0.53	0.86	-0.62	0.89	-0.9		0.35	-0.78	0.91
Short Term Debt	0.07	0.17	-0.39	-0.75	-0.66	0.22	-0.58	-0.29	0.18	0.42	0.14	-0.61	0.35		-0.66	0.65
Common Stock	-0.38	-0.4	0.72	0.79	0.5	-0.4	0.37	-0.16	-0.4	0.02	-0.48	0.89	-0.78	-0.66		-0.91
Current Deferred Revenue	0.64	0.65	-0.91	-0.94	-0.43	0.72	-0.34	0.34	0.66	-0.28	0.69	-0.99	0.91	0.65	-0.91

Click cells to compare fundamentals

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Competition

Predict SAB Biotherapeutics

SAB Dividend Paid And Capex Coverage Ratio

Dividend Paid And Capex Coverage Ratio

(121.04)

At this time, SAB Biotherapeutics' Dividend Paid And Capex Coverage Ratio is fairly stable compared to the past year.

Based on the recorded statements, SAB Biotherapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Portfolio Diagnostics Now

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings

All Next

Launch Module

SAB Fundamentals

	Return On Equity	-1.75
	Return On Asset	-0.79
	Operating Margin	(34.23) %
	Number Of Shares Shorted	4.32 K
	Price To Earning	0.21 X
	Revenue	2.24 M
	EBITDA	(38.08 M)
	Net Income	(42.19 M)
	Total Debt	5.91 M
	Book Value Per Share	4.00 X
	Cash Flow From Operations	(25.12 M)
	Earnings Per Share	0.29 X
	Number Of Employees	57
	Beta	0.64
	Total Asset	83.94 M
	Retained Earnings	(90.06 M)
	Working Capital	48.09 M
	Net Asset	83.94 M

About SAB Biotherapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC